Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management
Description
The presentation discusses complex cases of autoimmune connective tissue diseases, focusing on two distinct patients. The first case is a 47-year-old man presenting with numerous flesh-colored waxy papules and signs suggestive of scleromyxedema, a rare disorder characterized by mucin deposition in the skin. Key diagnostic features include the presence of unique papules, leonine facies, and a negative prayer sign. The condition is often associated with IgG lambda paraproteinemia but rarely progresses to multiple myeloma. IVIG is highlighted as the first-line treatment, showing promising results in clinical trials, with a need for ongoing maintenance therapy. A notable response was observed in the patient following two IVIG treatments, demonstrating significant skin and symptom improvement. The second case involves a 39-year-old man with indurated fibrotic plaques following the use of anabolic steroids and experiencing kidney failure and hypercalcemia. Initially suspected of nephrogenic systemic fibrosis, his condition was ultimately diagnosed as silicone-induced granulomas due to injectable materials used in body-building practices. The need for professional vigilance regarding atypical sclerotic presentations and the potential risks of unregulated silicone use in cosmetic procedures is emphasized. These cases illustrate the importance of thorough history-taking, recognition of unique clinical features, and multidisciplinary care in managing complex connective tissue diseases.
View moreConclusions
- Scleromyxedema is a rare sclerotic mucinous depositional disorder with significant clinical features such as shiny monomorphic papules and potential for multi-systemic involvement.
- The presence of IgG lambda paraproteinemia is strongly associated with scleromyxedema, though development into multiple myeloma is rare.
- High-dose IVIG is the first-line treatment for cutaneous and systemic manifestations of scleromyxedema and often requires ongoing maintenance therapy to prevent relapse.
- A prospective trial has shown that IVIG leads to substantial clinical improvement in scleromyxedema patients despite stable paraprotein levels in some cases.
- Scleromyxedema can lead to life-threatening systemic manifestations requiring thorough clinical review and appropriate lab investigations.
- Patients with scleromyxedema can experience various systemic issues including neurological and respiratory complications, reinforcing the need for comprehensive care.
- Relapses following the cessation of IVIG treatment highlight the chronic nature of scleromyxedema, underlining the importance of long-term management.
- In cases of atypical presentations of sclerosing skin diseases, alternative causes such as silicone-induced fibrosis should be considered, as they may also lead to serious complications like renal failure.
- Path: Elston's Dermatopathology. 2nd Ed.
- PMID: 28370513. High-dose IVIG for scleromyxedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. 2017.